Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astrana Health Inc. filings document the regulatory record for a physician-centric, technology-enabled healthcare management company. Current reports on Form 8-K furnish operating results, earnings presentations, Regulation FD materials, and investor-presentation exhibits tied to the company's care model, provider networks, technology platform, and financial performance.
Proxy filings cover annual-meeting governance matters, including director elections, auditor ratification, executive compensation votes, and equity incentive plan approvals. Other filings address reporting status through Form 12b-25 notices and material-event disclosures related to completed acquisitions, including acquired-business financial statements and pro forma operating information.
Astrana Health, Inc. announced that Chief Accounting Officer and principal accounting officer Glenn Sobotka will retire from his positions effective August 7, 2026. The company states his retirement is not due to any disagreement regarding operations, policies, or practices.
John Vong, currently Group Vice President, Accounting, has been appointed Senior Vice President – Accounting effective July 1, 2026 and will become principal accounting officer on August 7, 2026. Vong, age 52, has extensive prior experience in senior accounting roles at Astrana Health and Prospect Medical Systems. Effective July 1, 2026, his annual base salary will be $320,000. The company notes there are no related-party transactions or family relationships requiring disclosure.
Astrana Health, Inc. CEO and President Brandon Sim reported routine equity activity related to restricted stock vesting. He surrendered 1,093 shares of Common Stock at $44.51 per share to cover tax withholding obligations tied to vested restricted stock, a non-market, F-code tax-withholding disposition.
After this event, he directly holds 1,245,292 Common Stock shares, which include 34,207 unvested restricted shares and multiple tranches of restricted stock units scheduled to vest in semi-annual installments beginning in late 2026, plus 1,420 shares acquired under the Employee Stock Purchase Plan. Indirectly, trusts associated with Sim hold 392,816 and 258,824 shares, for which he disclaims beneficial ownership except for any pecuniary interest.
Schmidt David reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director David Schmidt received a grant of 4,525 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost to him under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. After this award, he holds a total of 36,019 common shares directly.
Mazdyasni Matthew reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health director Matthew Mazdyasni received an equity grant. The Form 4 reports an award of 4,525 shares of Astrana Health common stock at no purchase price, granted under the company’s 2024 Equity Incentive Plan.
These restricted shares will vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders. After this grant, Mazdyasni directly owns 39,288 shares of Astrana Health common stock, including the 4,525 unvested restricted shares.
Kitayama Mitchell W reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director Mitchell W. Kitayama received a grant of 4,991 shares of restricted common stock as equity compensation. The award was granted at no cash cost per share under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Kitayama directly holds a total of 32,837 shares of Astrana Health common stock, including the unvested restricted shares.
Dong Linda reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director Linda Dong received an equity award of 4,525 shares of restricted common stock. The grant was made under the company’s 2024 Equity Incentive Plan. These restricted shares will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Dong directly holds 97,133 shares of Astrana Health common stock, including the unvested restricted shares.
Dai, Weili reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health director Weili Dai received a grant of 4,525 shares of restricted common stock under the company’s 2024 Equity Incentive Plan. These shares vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual stockholders meeting, bringing Dai’s direct holdings to 18,188 shares.
Astrana Health, Inc. reported that director John Chiang acquired 4,525 shares of restricted common stock as a compensation award under the company’s 2024 Equity Incentive Plan. These restricted shares vest on the earlier of June 10, 2027 or the company’s 2027 annual stockholders’ meeting, after which he will fully own them. Following this grant, Chiang directly holds 35,373 shares of Astrana Health common stock.
Astrana Health, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which increases the shares of common stock reserved for issuance by 1,000,000 shares and extends the plan’s term until March 24, 2036. All director nominees were elected and the appointment of the independent registered public accounting firm was ratified. An advisory vote on executive compensation passed, and the equity plan received strong support, with 34,679,879 votes in favor. The meeting had a quorum, with 43,772,595 shares represented, about 78.6% of the 55,713,532 shares outstanding as of the record date.
Astrana Health, Inc. COO and CFO Basho Chandan reported a routine share surrender to cover taxes on vested equity. On May 16, 2026, he surrendered 8,155 shares of common stock at an indicated value of $38.26 per share to satisfy tax withholding obligations on restricted stock that vested that day.
After this tax-withholding disposition, Chandan directly owns 159,610 shares of Astrana Health common stock. This total includes 15,202 shares of unvested restricted stock scheduled to vest on May 16, 2027, as well as 15,604 restricted stock units vesting in four equal semi-annual installments beginning October 2, 2026 and 20,027 restricted stock units vesting in six equal semi-annual installments beginning September 5, 2026, all subject to continued employment.